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The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in
metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel
100mgm
 2 (D) with the combination of docetaxel 80mgm
 2 and epirubicin 75mgm
 2 (ED). The response rate (72 vs 79%), the
progression-free survival (median 9 vs 11 months) and the overall survival (median 18 vs 21 months) were not significantly different
between the ED (n¼26) and D arms (n¼25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In
conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an
anthracycline-based adjuvant or neoadjuvant therapy.
British Journal of Cancer (2006) 94, 1233–1236. doi:10.1038/sj.bjc.6603096 www.bjcancer.com
Published online 18 April 2006
& 2006 Cancer Research UK
Keywords: epirubicin; docetaxel; metastatic breast cancer; randomised trials; adjuvant anthracyclines
                                            
Anthracyclines are among the most active agents in the treatment
of metastatic and adjuvant breast cancer (Fossati et al, 1998;
EBCTCG, 2004). Docetaxel is the only agent that has demonstrated
survival benefits in anthracycline-resistant patients (Nabholtz
et al, 1999) and superior activity over doxorubicin as first-line
chemotherapy in patients previously treated with alkylating agents
(Chan et al, 1999). Owing to its activity and to the lack of cross-
resistance with anthracyclines, there is a strong rationale for
combining docetaxel with anthracyclines. The anthracycline-
taxane regimens can now be considered the most effective
regimens in metastatic breast cancer (MBC) and a first-line
therapy of choice in this set of patients (Valero and Hortobagyi,
2003). In particular, many reports have described the combined
use of docetaxel and epirubicin, an anthracycline less cardiotoxic
than doxorubicin, with the objective to find the safest and most
efficient way to integrate these classes of drugs (Mavroudis et al,
2000; Pagani et al, 2000). However, whether an anthracycline-
taxane regimen is worthy as first-line treatment for MBC patients
pretreated with adjuvant or neoadjuvant anthracyclines is an open
question, not definitely assessed by appropriate prospective trials.
Therefore, we planned a randomised phase III trial to compare
epirubicin and docetaxel vs docetaxel alone for efficacy and safety
as first-line chemotherapy of MBC patients pretreated with
epirubicin in adjuvant or neoadjuvant setting.
MATERIALS AND METHODS
Eligibility criteria were: women with MBCp65 years; no previous
chemotherapy for metastatic disease; measurable disease; Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2;
previous adjuvant or neoadjuvant chemotherapy with anthra-
cyclines, up to a total dose of doxorubicin p250mgm
 2 or
epirubicin p500mgm
 2, completed at least 12 months before
enrollment; absence of brain metastases; adequate bone marrow,
renal and liver function; left ventricular ejection fraction (LVEF)
X50%. Previous adjuvant endocrine therapy as well as endocrine
therapy for metastatic disease were allowed. Patients were
excluded if they had received taxanes as adjuvant chemotherapy
or had history of serious medical conditions potentially compro-
mising study participation. Pregnant or lactating women were
ineligible. All patients were required to provide written informed
consent and the protocol was approved by the Independent Ethical
Committee of the National Cancer Institute of Naples.
Patients were randomly assigned to docetaxel 100mgm
 2 (Arm
D) or to epirubicin 75mgm
 2 and docetaxel 80mgm
 2 (Arm ED)
on day 1, every 3 weeks for six cycles of chemotherapy, unless
disease progression or unacceptable toxicity. Prednisone and a
prophylactic antiemetic regimen with 5-HT3 antagonists were
given from the first infusion. No dose reduction of chemotherapy
was planned by protocol. Treatment was delayed for 1 week for
grade X2 neutropenia and/or grade X1 thrombocytopenia.
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sGranulocyte colony-stimulating factor (G-CSF) was administered
at 5mcgkgday
 1 subcutaneously in case of grade 4 neutropenia
until neutrophil count 42000mm
 3.
Pretreatment evaluation, performed within 1 month before
randomisation, included physical examination, laboratory studies,
ECG, echocardiography with LVEF, brain, chest and abdomen
computed tomography, bone scan, skeletal radiographs (if
required). Echocardiography and evaluation of tumour response,
according to Response evaluation criteria in solid tumor (RECIST)
guidelines, were performed every three cycles.
Toxicity was evaluated according to National Cancer Institute
Common Toxicity Criteria version 2.0. For each type of toxicity,
the worst degree experienced throughout the treatment was
computed for each patient.
The study was designed as a single centre randomised phase III
study with response rate as primary end point. Stratification
factors were: performance status (0 vs 1 vs 2), disease-free survival
(o24 months vs 424 months) and type of dominant metastatic
site (soft tissue vs bone vs viscera). Primary objective was to
evaluate the objective response rate (ORR) of docetaxel and
epirubicin compared with docetaxel alone. Secondary end points
included toxicity, progression-free survival (PFS) and overall
survival. Calculation of sample size was based on a 40% expected
response rate with docetaxel alone, a 60% auspicated response rate
with the combination of docetaxel and doxorubicin, a 20% of risk
of false negative and a 5% of risk of false positive result, and a one-
tailed w
2 test. With these requirements, planned sample size was 77
patients for each arm of treatment. Continuous and ordinal
categorical data were compared by exact Wilcoxon rank sum test.
Dichotomous data were compared by Fisher’s exact test. Progres-
sion-free and overall survival curves were drawn according to
Kaplan–Meier and statistical significance of differences was tested
by the log-rank test. As the study was interrupted earlier than
planned, the Bayesian predictive probability that the response rate
of the ED group would be statistically better than that of the D
group, if the trial were continued to the planned end, was
calculated to corroborate the meaning of findings (Johns and
Andersen, 1999).
RESULTS
From May 2000 to October 2003, 51 patients were enrolled. The
recruitment was slower than expected, due to the restrictive
inclusion criteria of the protocol and prompted us to stop the
study, after 3.5 years, because time needed to reach the planned
sample size would have been too long. Baseline characteristics of
the patients were well balanced between the two arms (Table 1).
The median number of administered cycles was six (range 2–6);
81 and 76% of patients received all the planned therapy (six cycles)
in the ED and D treatment arms, respectively. Median average
relative dose intensity of treatment was similar in the two groups,
while G-CSF was used far more frequently in ED group; 77% of ED
subjects, indeed, used G-CSF in at least one cycle compared with
56% of D patients (P¼0.0582).
All the responses were independently validated. Both therapeu-
tic regimens showed similar antitumour activity (Table 2). The
Table 1 Baseline characteristics of patients
Variable
Overall
(N¼51) ED (N¼26) D (N¼25)
Age, median (range) 51 (35–64) 51 (38–64) 51 (35–63)
Menopausal status, n (%)
Premenopausal 9 (18) 5 (19) 4 (16)
Postmenopausal 42 (82) 21 (81) 21 (84)
Performance status, n (%)
0 32 (63) 16 (62) 16 (64)
1 18 (35 9 (35) 9 (36)
2 1 (2) 1 (4) —
Disease-free interval, median
(range) months
31 (8–138) 33 (8–138) 30 (11–78)
Disease-free interval, n (%)
p2 years 11 (22) 6 (23) 5 (20)
42 years 40 (78) 20 (77) 20 (80)
Dominant metastatic site, n (%)
Soft tissues 21 (41) 12 (46) 9 (36)
Bone 1 (2) — 1 (4)
Viscera 29 (57) 14 (54) 15 (60)
Previous radiation following conservative surgery
No 30 (59) 17 (65) 13 (52)
Yes 21 (41) 9 (35) 12 (48)
Previous dose of anthracycline,
median (range), (mgm
 2)
440 (150–500) 440 (150–480) 440 (300–500)
Time from last anthracycline,
median (range), (months)
37 (12–131) 35 (12–131) 37 (18–83)
Table 2 Outcomes
Variable Overall (N¼51) ED (N¼26) D (N¼25) P
a
Objective response analysis, n (%)
Not eligible 2 (4) 1 (4) 1 (4)
Eligible 49 (96) 25 (96) 24 (96)
Best response, n (% of eligible patients)
Complete 10 (20) 4 (16) 6 (25)
Partial 27 (55) 14 (56) 13 (54)
Stable disease 7 (14) 4 (16) 3 (12)
Progressive disease, 4 (8) 3 (12) 1 (4)
Not assessed 1 (2) — 1 (4)
Objective response rate, % (95% exact CI) 76 (61–87) 72 (51–88) 79 (58–93) 0.8196
b
Time to progression (TTP) 0.6998
c
Events, n (%) 45 (88) 22 (85) 23 (92)
Median (95% confidence interval) TTP, (months) 10 (8–12) 9 (7–13) 11 (9–15)
Overall survival 0.6406
c
Events, n (%) 30 15 15
Median (95% confidence interval) overall survival, (months) 20 (17-na) 18 (15-na) 21 (18-na)
aOne-tailed P-values.
bFrom Fisher exact test.
cFrom Log-rank test.
Epirubicin in MBC treated with adjuvant anthracyclines
C Pacilio et al
1234
British Journal of Cancer (2006) 94(9), 1233–1236 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sORR was 72% (18 patients; 95% exact CI: 51–88) in the ED arm
and 79% (19 patients; 95% exact CI: 58–93) in the D arm (one-
tailed P¼0.8196). Based on these results, the probability that the
response rate of the ED group would be significantly better than
that of the D group, if the trial were brought to its completion, is
equal to 0.0334.
After 45 (88%) events, the median progression-free survival was
9 months in the ED and 11 months in the D arm (one-tailed
P¼0.6998). With regard to overall survival, 30 events (15 in each
arm) were reported after a 30 months median follow-up of alive
patients. The median overall survival was 18 months in the ED and
21 months in the D arm (one-tailed P¼0.6406). Progression-free
and overall survival curves are reported in Figure 1.
Haematological and nonhaematological toxicities are sum-
marised in Table 3. Leucopaenia, the most frequent haematological
toxicity, was significantly more severe in the ED arm (P¼0.0290).
Among nonhaematological toxicities, nausea and stomatitis were
significantly worse in the ED arm (P¼0.0210 and P¼0.0499,
respectively). No significant differences between the arms were
found in other nonhaematological toxicities. Grade 1 cardiac
toxicity was reported in 19 and 16% of patients, with ED and D,
respectively (P¼0.9999).
DISCUSSION
Our phase III study indicates that the addition of epirubicin to
docetaxel did not improve outcomes as compared to single-agent
docetaxel, in the first-line treatment of metastatic breast cancer
patients, who already had received adjuvant epirubicin. Both
therapeutic regimens showed similar antitumour activity, and no
significant differences were found between the two treatments in
progression-free survival and overall survival. Of course, we are
aware that the small sample size and the fact that enrollment was
stopped before than planned are major limitations of our study.
However, our results are strengthened by the finding that the
Bayesian predictive probability that the study hypothesis (that ED
could increase by a 20% the response rate as compared with D
alone) could be eventually demonstrated if the study had reached
the planned sample size is definitely low (only 3.3%). To the best of
our knowledge, there is no randomised study addressing the
role of anthracyclines in the treatment of patients relapsing
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Figure 1 Kaplan–Meier estimated progression-free (top) and overall
survival (bottom) curves scattered by treatment arm (D¼blue dotted line;
ED¼red solid line).
Table 3 Worst per-patient toxicity according to NCI-CTC grade
a
ED (N¼26) D (N¼25)
Type of toxicity 0123401234 P
b
Allergy 96 — 4 — — 92 4 4 — — 0.9700
Anemia 62 27 4 8 — 72 28 — — — 0.3315
Leukopenia 15 — 12 38 35 20 — 28 48 4 0.0290
Neutropenia 12 — 4 8 77 20 — 4 16 60 0.2453
Febbrile neutropenia 88 — — 12 — 92 — — 4 4 0.9999
Platelets 96 4 — — — 100 — — — — 0.9999
Heart 81 19 — — — 84 16 — — — 0.9999
Fatigue 50 27 19 4 — 60 24 16 — — 0.4210
Fever 85 15 — — — 84 16 — — — 0.9999
Weight loss 96 — 4 — — 100 — — — — 0.9999
Hair loss 27 — 73 24 — 76 0.9999
Skin 92 8 — — — 88 4 8 — — 0.5162
Anorexia 77 23 — — — 96 4 — — — 0.1108
Constipation 92 8 — — — 92 4 4 — — 0.9700
Diarrhoea 46 23 27 4 — 28 36 32 4 — 0.3320
Nausea 27 46 23 4 — 60 28 12 — — 0.0210
Stomatitis 31 42 15 12 — 56 32 12 — — 0.0499
Vomiting 58 27 15 — — 80 16 4 — — 0.0968
Liver 96 — — 4 — 96 — — 4 — 0.9999
Motor neuropathy 92 8 — — — 92 8 — — — 0.9999
Sensorial neuropathy 88 12 — — — 84 16 — — — 0.9543
DIC 96 — — 4 — 100 — — — — 0.9999
RBC transfusion 96 — — 4 — 100 — — — — 0.9999
aRow percentages are reported; sum can be different from 100 because of rounding.
bTwo-tailed P-values from exact Wilcoxon–Mann–Whitney test. Bold values are
statistically significant.
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studies, indirectly addressing this issue, have produced conflicting
results. Chauvin et al (1990) demonstrated a low activity of the
CEF regimen in patients previously treated with anthracycline-
based adjuvant chemotherapy. Other authors (Venturini et al,
1996; Pierga et al, 2001) found that previous adjuvant chemother-
apy could adversely affect the prognosis of MBC patients treated
with an anthracycline-based first-line chemotherapy, but this effect
was independent of whether adjuvant chemotherapy was CMF- or
anthracycline-based. On the contrary, other studies (Buzdar et al,
1981; Valagussa et al, 1986; Kardinal et al, 1988; Gennari et al,
2004) did not demonstrate a poorer outcome in metastatic breast
cancer patients previously treated with adjuvant chemotherapy.
Namely, Gennari et al (2004) did not find any negative influence of
adjuvant anthracyclines on the activity of first-line epirubicin and
paclitaxel, confirming that modern chemotherapy regimens,
including anthracyclines and taxanes, provide satisfactory results
in metastatic breast cancer patients, regardless of previous
adjuvant chemotherapy.
In conclusion, the results of our trial support that epirubicin
should not be included in taxanes-containing regimens for breast
cancer patients relapsed after an anthracycline-based adjuvant or
neoadjuvant therapy, also taking into account the availability for
these patients of new active, non-cross-resistant drugs.
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